Country: Israel
Language: English
Source: Ministry of Health
OXYGEN
MAXIMA AIR SEPARATION LTD, ISRAEL
V03AN01
GAS - MEDICINAL, COMPRESSED
OXYGEN 21.0 - 22.5 %V/V
INHALATION
Required
MAXIMA AIR SEPARATION CENTER LTD, ISRAEL
OXYGEN
Gas for inhalation
2018-12-18
_This leaflet format has been determined by the Ministry of Health and the content has been _ _checked and approved in December 2018_ _ _ Physician Prescribing Information Air, Synthetic Medicinal Summary of Product Characteristics (SPC) 1. NAME OF THE MEDICINAL PRODUCT Air, Synthetic Medicinal 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Medical air specification. oxygen content: 21.0%- 22.5% v/v The medical air cylinder specification complies with the European Pharmacopoeia monograph (1684). 3. PHARMACEUTICAL FORM Medicinal gas, compressed. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Gas for Inhalation 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For breathing purposes medical air is administered by various means, commonly by self contained or compressed air line breathing apparatus. In anaesthesia, medical air is administered via a cylinder and valve assembly through a face mask or endotracheal tube. 4.3 CONTRAINDICATIONS Medical air is contraindicated where oxygen or other gaseous combinations would be indicated (airways obstruction, pneumonia, and a myriad of cardio-respiratory conditions). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Medical air should never be administered to a patient if, when it is mixed with other gases, the oxygen content is less than 21%. Care is needed in the handling and use of medical air cylinders. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None applicable. 4.6 PREGNANCY AND LACTATION Medical air does not adversely affect pregnancy and lactation. 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES The use of medical air does not affect the ability to drive or use machinery. 4.8 UNDESIRABLE EFFECTS None applicable. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by u Read the complete document